MétaCan
Menu
Back to cohort
Record W4405659418 · doi:10.1093/brain/awae409

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

2024· review· en· W4405659418 on OpenAlexafffund
G. Androdias, Jan D. Lünemann, Élisabeth Maillart, Maria Pia Amato, Bertrand Audoin, Arlette L. Bruijstens, Gabriel Bsteh, Helmut Butzkueven, Olga Ciccarelli, Álvaro Cobo‐Calvo, Tobias Derfuß, Franziska Di Pauli, Gilles Edan, Christian Enzinger, Ruth Geraldes, Cristina Granziera, Yael Hacohen, Hans‐Peter Hartung, Sinéad M. Hynes, Matilde Inglese, Ludwig Kappos, Hanna Kuusisto, Annette Langer‐Gould, Melinda Magyari, Romain Marignier, Xavier Montalbán, Marcin P. Mycko, Bardia Nourbakhsh, Jiwon Oh, Celia Oreja‐Guevara, Fredrik Piehl, Luca Prosperini, Jaume Sastre‐Garriga, Finn Sellebjerg, Krzysztof Selmaj, Aksel Sıva, Emma Tallantyre, Vincent van Pesch, Sandra Vukusic, Bianca Weinstock‐Guttman, Frauke Zipp, Mar Tintoré, Ellen Iacobaeus, Bruno Stankoff

Bibliographic record

VenueBrain · 2024
Typereview
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsUniversity of TorontoSt. Michael's Hospital
FundersCilagInstituto de Salud Carlos IIIJanssen PharmaceuticalsSanofi GenzymeChugai PharmaceuticalNovartis PharmaStrategic Research CouncilEMD SeronoMedDay PharmaceuticalsTaysUniversity College London Hospitals NHS Foundation TrustDeutsche ForschungsgemeinschaftBayer HealthCareMultiple Sclerosis SocietyNational Institute for Health and Care ResearchGalápagosFondation pour l'Aide à la Recherche sur la Sclérose en PlaquesArgenxCelltrionShionogiMerck KGaAKiniksa PharmaceuticalsNational Institutes of HealthMylanH. Lundbeck A/SHorizon TherapeuticsMonash UniversitySanofiTG TherapeuticsGenentechEuropean CommissionFondation Brain CanadaEuropean Committee for Treatment and Research in Multiple SclerosisBundesministerium für Bildung und ForschungMax-Planck-GesellschaftAtara BiotherapeuticsTürkiye Bilimsel ve Teknolojik Araştırma KurumuBiogenAgence Nationale de la RechercheF. Hoffmann-La RocheAlexion PharmaceuticalsBristol-Myers SquibbTeva Pharmaceutical IndustriesEli Lilly and CompanyU.S. Department of DefenseMultiple Sclerosis International FederationCelgeneModernaInternational Progressive MS AllianceNational Multiple Sclerosis SocietyIstanbul Üniversitesi-CerrahpasaGlaxoSmithKlinePatient-Centered Outcomes Research InstituteAmgen
KeywordsMultiple sclerosisMedicineDiseaseIntensive care medicineModalitiesPsychiatryPathology

Abstract

fetched live from OpenAlex

The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs after disease onset is associated with a better long-term prognosis. However, the question of when and how to de-escalate or discontinue DMTs remains open and critical. This topic was discussed during an international focused workshop organized by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in 2023. The aim was to review the current evidence on the rationale for, and the potential pitfalls of, treatment de-escalation in MS. Several clinical scenarios emerged, mainly driven by a change in the benefit-risk ratio of DMTs over the course of the disease and with ageing. The workshop also addressed the issue of de-escalation by the type of DMT used and in specific situations, including pregnancy and paediatric onset MS. Finally, we provide practical guidelines for selecting appropriate patients, defining de-escalation and monitoring modalities and outlining unmet needs in this field.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.976
Threshold uncertainty score0.926

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.207
GPT teacher head0.396
Teacher spread0.189 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations25
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueBrainSame topicMultiple Sclerosis Research StudiesFrench-language works237,207